Penelope Ward

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6025378/publications.pdf Version: 2024-02-01



DENELODE WAD

#	Article	IF	CITATIONS
1	Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza. JAMA - Journal of the American Medical Association, 2000, 283, 1016.	7.4	909
2	Oral oseltamivir treatment of influenza in children. Pediatric Infectious Disease Journal, 2001, 20, 127-133.	2.0	684
3	Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human Influenza. JAMA - Journal of the American Medical Association, 1999, 282, 1240.	7.4	500
4	Use of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent Influenza. New England Journal of Medicine, 1999, 341, 1336-1343.	27.0	477
5	Impact of Oseltamivir Treatment on Influenza-Related Lower Respiratory Tract Complications and Hospitalizations. Archives of Internal Medicine, 2003, 163, 1667.	3.8	443
6	Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802. Clinical Pharmacokinetics, 1999, 37, 471-484.	3.5	361
7	Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic. Journal of Antimicrobial Chemotherapy, 2005, 55, i5-i21.	3.0	357
8	Management of Influenza in Households: A Prospective, Randomized Comparison of Oseltamivir Treatment With or Without Postexposure Prophylaxis. Journal of Infectious Diseases, 2004, 189, 440-449.	4.0	301
9	Long-Term Use of Oseltamivir for the Prophylaxis of Influenza in a Vaccinated Frail Older Population. Journal of the American Geriatrics Society, 2001, 49, 1025-1031.	2.6	168
10	Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine () Tj ETQq0 0 0 rg Biochemically Recurrent Prostate Cancer. Journal of Urology, 2017, 197, 676-683.	3T /Overloo 0.4	ck 10 Tf 50 3 165
11	The Impact of Positron Emission Tomography with ¹⁸ F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. Journal of Urology, 2019, 201, 322-331.	0.4	113
12	A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. Journal of Antimicrobial Chemotherapy, 2003, 51, 977-990.	3.0	102
13	Oral Oseltamivir in Human Experimental Influenza B Infection. Antiviral Therapy, 2000, 5, 205-213.	1.0	81
14	Effect of age and gender on tirilazad pharmacokinetics in humans. Clinical Pharmacology and Therapeutics, 1994, 55, 378-384.	4.7	75
15	The Pharmacokinetics and Tolerability of the Oral Neuraminidase Inhibitor Oseltamivir (Ro) Tj ETQq1 1 0.784314 836-843.	rgBT /Ove 2.0	rlock 10 Tf 5 71
16	Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1?5�years. European Journal of Clinical Pharmacology, 2003, 59, 411-415.	1.9	66
17	The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephrology Dialysis Transplantation, 2006, 21, 2556-2562.	0.7	63
18	Viral Respiratory Infection in Schoolchildren: Effects on Middle Ear Pressure. Pediatrics, 2002, 109, 826-832.	2.1	60

PENELOPE WARD

#	Article	IF	CITATIONS
19	Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using ¹⁸ F-Fluciclovine PET/CT. Journal of Nuclear Medicine, 2017, 58, 1596-1602.	5.0	33
20	Smoking and DNA damage in cervical cells. Lancet, The, 1990, 335, 417.	13.7	22
21	Lack of Pharmacokinetic Interaction between the Oral Anti-Influenza Prodrug Oseltamivir and Aspirin. Antimicrobial Agents and Chemotherapy, 2002, 46, 1993-1995.	3.2	22
22	Antivirals for influenza in healthy adults. Lancet, The, 2006, 367, 1571.	13.7	16
23	Pilot study of the efficacy of atevirdine in the treatment of AIDS dementia complex. Aids, 1996, 10, 1357-1360.	2.2	12
24	18F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE. Practical Radiation Oncology, 2020, 10, 354-362.	2.1	9